Pharmacogenomics of Drug Safety-Reference-Cited by-同舟云学术

Pharmacogenomics of Drug Safety

Published:2023 Issue: Volume: Page:413-437
ISSN:
Container-title:Pharmacogenomics in Clinical Practice
language:en
Short-container-title:

Author:

Vukadin Sonja,Petrović Ana,Primorac Dragan,Smolić Martina

Publisher

Springer International Publishing

Link

https://link.springer.com/content/pdf/10.1007/978-3-031-45903-0_23

Reference50 articles.

1. Gammal RS, Court MH, Haidar CE, Iwuchukwu OF, Gaur AH, Alvarellos M, et al. Clinical pharmacogenetics implementation consortium (CPIC) Guideline for UGT1A1 and atazanavir prescribing. Clin Pharmacol Ther. 2016;99(4):363–9. https://doi.org/10.1002/cpt.269.

2. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27(5):699–711. https://doi.org/10.1016/S0893-133X(02)00346-9.

3. Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727–38. https://doi.org/10.1016/S2215-0366(18)30269-4.

4. Brown JT, Bishop JR, Sangkuhl K, Nurmi EL, Mueller DJ, Dinh JC, et al. Clinical pharmacogenetics implementation consortium guideline for cytochrome P450 (CYP)2D6 genotype and atomoxetine therapy. Clin Pharmacol Ther. 2019;106(1):94–102. https://doi.org/10.1002/cpt.1409.

5. Dragan P, Wolfgang H, editors. Pharmacogenetics in clinical practice: experience with 55 commonly used drugs. Zagreb, Hamburg, Philadelphia: St. Catherine Specialty Hospital, Republic of Croatia; 2021.